In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In silico
molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor
Authors
Keywords
-
Journal
Molecular Oncology
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-10-06
DOI
10.1002/1878-0261.12810
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma
- (2020) Vijay M. Patil et al. Cancer Medicine
- MolTarPred: a web tool for comprehensive target prediction with reliability estimation
- (2019) Antonio Peón et al. Chemical Biology & Drug Design
- Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer
- (2018) Yoon-Jae Kim et al. CANCER LETTERS
- Virtual Fragment Screening Identification of a Quinoline-5,8-dicarboxylic Acid Derivative as a Selective JMJD3 Inhibitor
- (2018) Assunta Giordano et al. ChemMedChem
- A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH -wildtype and IDH -mutant gliomas
- (2018) Peter Wirthschaft et al. INTERNATIONAL JOURNAL OF CANCER
- Kinase-targeted cancer therapies: progress, challenges and future directions
- (2018) Khushwant S. Bhullar et al. Molecular Cancer
- Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing
- (2018) Jenny Rubin et al. Oncotarget
- Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma
- (2018) Christine G. Skibinski et al. JOURNAL OF NEURO-ONCOLOGY
- The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation
- (2017) Kristin Blom et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas
- (2017) Franciele Cristina Kipper et al. INVESTIGATIONAL NEW DRUGS
- In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery
- (2017) Yanli Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors
- (2017) Michelle De Witt et al. MOLECULAR MEDICINE
- Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease
- (2017) Jong Kil Lee et al. MOLECULES
- The high price of anticancer drugs: origins, implications, barriers, solutions
- (2017) Vinay Prasad et al. Nature Reviews Clinical Oncology
- Label-free quantitative proteomics unravels the importance of RNA processing in glioma malignancy
- (2017) Baibin Bi et al. NEUROSCIENCE
- In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells
- (2017) S. R. Lai et al. Veterinary and Comparative Oncology
- The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma
- (2017) Cynthia M. Simbulan-Rosenthal et al. Oncotarget
- Zinc binding to RNA recognition motif of TDP-43 induces the formation of amyloid-like aggregates
- (2017) Cyrille Garnier et al. Scientific Reports
- Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
- (2017) J. Javier Hernandez et al. Frontiers in Oncology
- Predicting the Reliability of Drug-target Interaction Predictions with Maximum Coverage of Target Space
- (2017) Antonio Peón et al. Scientific Reports
- The ChEMBL database in 2017
- (2016) Anna Gaulton et al. NUCLEIC ACIDS RESEARCH
- Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model
- (2016) Tara Williamson et al. Oncotarget
- TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1
- (2016) M. B. Hossain et al. Science Advances
- Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas
- (2015) Alfeu Zanotto-Filho et al. CANCER LETTERS
- The Stress Kinase p38 as a Target for Cancer Therapy
- (2015) A. Igea et al. CANCER RESEARCH
- A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Drug repurposing in oncology—patient and health systems opportunities
- (2015) Francesco Bertolini et al. Nature Reviews Clinical Oncology
- Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential
- (2015) Santosh Chauhan et al. Nature Communications
- Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor
- (2014) A. R. Larsen et al. MOLECULAR CANCER THERAPEUTICS
- Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis
- (2014) Ren-Yuan Bai et al. NEURO-ONCOLOGY
- β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
- (2013) E Pasquier et al. BRITISH JOURNAL OF CANCER
- Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK
- (2013) Lorena Pereira et al. EMBO Molecular Medicine
- Has the time come for metronomics in low-income and middle-income countries?
- (2013) Nicolas André et al. LANCET ONCOLOGY
- Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
- (2013) R. M. Campbell et al. MOLECULAR CANCER THERAPEUTICS
- MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy
- (2012) Salome Paillas et al. Autophagy
- A consistent description of HYdrogen bond and DEhydration energies in protein–ligand complexes: methods behind the HYDE scoring function
- (2012) Nadine Schneider et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- Predicting New Indications for Approved Drugs Using a Proteochemometric Method
- (2012) Sivanesan Dakshanamurthy et al. JOURNAL OF MEDICINAL CHEMISTRY
- p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells
- (2012) Yiu To Yeung et al. JOURNAL OF NEURO-ONCOLOGY
- Polypharmacology: drug discovery for the future
- (2012) A Srinivas Reddy et al. Expert Review of Clinical Pharmacology
- Morphometic analysis of TCGA glioblastoma multiforme
- (2011) Hang Chang et al. BMC BIOINFORMATICS
- Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
- (2011) Ren-Yuan Bai et al. NEURO-ONCOLOGY
- Gene expression and network-based analysis reveals a novel role for hsa-miR-9 and drug control over the p38 network in glioblastoma multiforme progression
- (2011) Rotem Ben-Hamo et al. Genome Medicine
- Empirical Scoring Functions for Advanced Protein−Ligand Docking with PLANTS
- (2009) Oliver Korb et al. Journal of Chemical Information and Modeling
- The topology of drug–target interaction networks: implicit dependence on drug properties and target families
- (2009) Jordi Mestres et al. Molecular BioSystems
- p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
- (2008) Kenji Ishitsuka et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
- (2008) N. Doudican et al. MOLECULAR CANCER RESEARCH
- Network pharmacology: the next paradigm in drug discovery
- (2008) Andrew L Hopkins Nature Chemical Biology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation